One of the two antibodies used in an experimental treatment for US President Donald Trump was developed using blood samples from three patients in Singapore, according to a report by Asian Science Magazine published on Monday.The science and technology publication noted that Trump had on Friday received a “high dose” of an experimental antibody therapy known as REGN-COV2 developed by American biotechnology company Regeneron.The treatment – a combination of two antibodies against the coronavirus…